Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
23.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.10. | Aprea Therapeutics to Present at Maxim 2024 Healthcare Virtual Summit | 3 | GlobeNewswire (USA) | ||
09.10. | APRE stock touches 52-week low at $2.22 amid market challenges | 1 | Investing.com | ||
09.10. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
09.10. | Aprea Therapeutics Engages Philippe Pultar, MD to Serve as Senior Medical Advisor and Lead WEE1 Clinical Development | 1 | GlobeNewswire (USA) | ||
09.09. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
04.09. | APRE stock touches 52-week low at $3.17 amid market challenges | 1 | Investing.com | ||
28.08. | Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference | 1 | GlobeNewswire (USA) | ||
21.08. | Aprea Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics GAAP EPS of -$0.58, revenue of $561.57M | 1 | Seeking Alpha | ||
12.08. | Aprea Therapeutics Inc reports results for the quarter ended in June - Earnings Summary | 1 | Reuters | ||
12.08. | APRE stock touches 52-week low at $3.22 amid market challenges | 1 | Investing.com | ||
12.08. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
12.08. | Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update | 107 | GlobeNewswire (Europe) | Enrollment commenced in the ACESOT-1051 Phase 1 trial evaluating APR-1051 - no myelosuppression observed in the first of eight planned cohorts at sub-therapeutic dose $28.7 million in cash and cash... ► Artikel lesen | |
12.08. | Aprea Therapeutics, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
21.06. | Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024 | 1 | GlobeNewswire (USA) | ||
17.06. | Aprea Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
17.06. | Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051 | 132 | GlobeNewswire (Europe) | APR-1051 is a highly selective and potentially best-in-class oral WEE1 inhibitor Phase 1 ACESOT-1051 clinical trial is evaluating APR-1051 as monotherapy treatment in patients with significant unmet... ► Artikel lesen | |
28.05. | Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial | 2 | GlobeNewswire (USA) | ||
14.05. | Aprea Therapeutics GAAP EPS of -$0.67 | 1 | Seeking Alpha |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,730 | +1,74 % | QIAGEN N.V.: QIAGEN erhält FDA-Zulassung für QIAstat-Dx Mini-Panel für eine präzisere ambulante Behandlung von Atemwegserkrankungen | QIAstat-Dx Respiratory Panel Mini erkennt die fünf relevantesten Erreger von Atemwegserkrankungen im ambulanten Bereich und hilft Ärzten dabei, präzise Behandlungsentscheidungen zu treffen // Mithilfe... ► Artikel lesen | |
ADMA BIOLOGICS | 19,245 | +18,00 % | ADMA Biologics jumps as KPMG becomes new auditor | ||
EVOTEC | 7,145 | +0,78 % | Aixtron, BB Biotech, Evotec, HelloFresh, Stabilus, TUI - 4investors Aktien Top-New | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
HARMONY BIOSCIENCES | 33,120 | +3,08 % | Harmony Biosciences Reports Strong Third Quarter 2024 Financial Results And Highlights Catalyst-rich, Late-stage Pipeline Poised To Deliver One Or More New Launches Every Year Over Next Five Years | WAKIX (pitolisant) Net Revenue of $186.0 Million for Third Quarter 2024; Surpassed $2B in Cumulative Net Revenue in Less Than Five Years
On Track to Submit sNDA... ► Artikel lesen | |
LONGBOARD PHARMACEUTICALS | 59,68 | -0,08 % | Longboard Pharmaceuticals, Inc.: Lundbeck to Acquire Longboard Pharmaceuticals in a Strategic Deal, Significantly Enhancing Its Neuroscience Pipeline | The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental... ► Artikel lesen | |
BIONTECH | 102,40 | -0,87 % | Biontech-Partner top in Q3: Pfizer übertrifft Erwartungen und hebt Jahresprognose an | © Foto: Foto: Nicolas Maeterlinck/ - BELGA/dpaPfizer hat starke Ergebnisse für das dritte Quartal präsentiert, die sowohl beim Umsatz als auch beim bereinigten Gewinn deutlich über den Analystenschätzungen... ► Artikel lesen | |
VIR BIOTECHNOLOGY | 9,160 | +22,30 % | Vir Biotechnology Reports Third Quarter 2024 Financial Results and Provides Corporate Update | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the third quarter ended September 30, 2024.
"This quarter... ► Artikel lesen | |
NUVALENT | 88,46 | -0,03 % | Nuvalent, Inc.: Nuvalent Highlights Pipeline Progress, Reiterates Key Anticipated Milestones, and Reports Second Quarter 2024 Financial Results | Company plans to host a conference call in conjunction with oral presentations at ESMO on September 14, 2024, at 8:30 a.m. ET / 2:30 p.m. CEST
$658.0 million in cash, cash equivalents and marketable... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 6,435 | +1,82 % | Recursion Pharmaceuticals-Direktor Blake Borgeson verkauft Aktien im Wert von 76.926 US-Dollar | ||
SUMMIT THERAPEUTICS | 18,860 | +1,45 % | Summit Therapeutics Aktie: Bleiben Sie wachsam! | Summit Therapeutics, ein biopharmazeutisches Unternehmen, verzeichnete am 26. Oktober 2024 einen bemerkenswerten Kursanstieg von 9,25% auf 21,26 USD. Dieser Aufschwung erfolgt trotz einer herausfordernden... ► Artikel lesen | |
AVIDITY BIOSCIENCES | 42,100 | -0,38 % | Avidity Biosciences target held at $59 by Goldman Sachs | ||
VERA THERAPEUTICS | 43,500 | +7,73 % | Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024 | Long-term improvements observed in the quartet of findings defining disease modification supports atacicept's potential to prevent kidney failure in patients with IgAN;Long-term results from the ORIGIN... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 47,100 | +5,87 % | Tarsus Pharmaceuticals stock hits 52-week high at $42.63 | ||
TANGO THERAPEUTICS | 5,130 | -5,61 % | TNGX-Aktie erreicht 52-Wochen-Tief bei 5,6 US-Dollar | ||
ATHIRA PHARMA | 0,625 | +45,99 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |